Jubilant Ingrevia Ltd. · NSE:JUBLINGREA
Jubilant Ingrevia — Emkay Confluence - Ideas for a $5trn Economy 2022
39 slides from Jubilant Ingrevia's conference presentation, Aug 8, 2022
Slide 1: Intimation of Investor/Analyst Meetings
August 8, 2022 BSE Limited National Stock Exchange of India Limited P. J. Towers Exchange Plaza Dalal Street, Bandra Kurla Complex Mumbai - 400 001 Bandra (E), Mumbai - 400 051 Scrip Code: 543271 Trading Symbol: JUBLINGREA Dear Sirs, Sub: Intimation of Investor/ Analyst Meetings Pursuant to the prov
Slide 2: List of participating investors
Sr. No Investors 1 Emkay Global Financial Services Limited 2 Bharti Axa Insurance 3 Birla Sun Life Insurance Co Ltd 4 ASK Investment Managers Pvt. Ltd 5 ICICI Prudential AMC 6 IDBI Mutual Fund 7 JM Financial Asset Management 8 Lucky Securities 9 Max Life Insurance 10 Rare Enterprise 11 Reliance Nipp
Slide 3: Investor Presentation August 2022
Investor Presentation August 2022
Slide 4: Disclaimer
Disclaimer Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential product characteristics and uses, product sales potential and target dates f
Slide 5: Company Overview
Company Overview
Slide 6: Jubilant Bhartia Group - Snapshot
Jubilant Bhartia Group - Snapshot Jubilant Bhartia Group founded by Shyam S Bhartia and Hari S Bhartia, leading industrialists from India Strong presence in diverse sectors like Pharmaceuticals, CDMO (Contract Research & Development Services) and Therapeutics, Specialty Chemicals, Nutraceutical Prod
Slide 7: Integrated Business Model
Integrated Business Model Jubilant Ingrevia Integrated Operations… 52% of our Pyridine & Picolines Speciality Nutrition & Health Chemical volume is used in-house for value- Chemicals Solutions Intermediates# added products in Speciality Nutrition & Pyridine & Chemicals & for Vitamin B3 Nutrition & H
Slide 8: Glorious Four Decades of Growth
Glorious Four Decades of Growth Commissioning of Our Journey 10+ years experience in 2019: Started new Acetic Anhydride plant, Bharuch SEZ, GJ (50 KTA) Phase1: Diketene 2018: Started Agro Intermediate plant (800 TPA), Bharuch SEZ Derivative Plant Vitamin B3 2017: Certified for Responsible Care (RC)
Slide 9: Company Snapshot
Company Snapshot Leadership Revenue Segmentation: By Region (FY’22) Total 1500+ customers - Globally # 1 in 17 Pyridine Derivatives • Speciality Chemicals: 470 - Globally among Top 2 in (Pyridine + Beta) N.America • Nutrition & Health Solutions: 460 RoW Domestic Sales 5% 10% for International • Chem
Slide 10: Executive Leadership Team
Executive Leadership Team Rajesh Srivastava Chief Executive Officer & Managing Director 35 years of industry experience Anil Khubchandani Chandan Singh Sumit Das Ashish Kumar Sinha Co-CEO & WTD Co-CEO SVP – Nutrition & VP – Animal & Human Speciality Chemicals Chemical Intermediates Health Ingredient
Slide 11: Multi Location Manufacturing & Operation Excellence
Multi Location Manufacturing & Operation Excellence Manufacturing Facilities 463 acres 310 acres 144 acres 109 acres 3.5 acres Gajraula, Uttar Pradesh, Bharuch, Gujarat, India Nira, Maharashtra, India Samlaya, Gujarat, India Ambernath, Maharashtra, India Speciality Chemicals, Chemical Intermediates
Slide 12: Research Development & Technology (RDT)
Research Development & Technology (RDT) 3 RDT centers in Noida, Gajraula and Bharuch 35 Key technology platforms developed & commercialized to global standards. Some are unique: Ammoxidation, Key Grignard etc. Highlights 92 highly qualified scientists (22 PhDs) 60+ Products in Pipeline for next 4 ye
Slide 13: End Usage Applications for Pharma, Agrochemicals & Nutraceuticals
End Usage Applications for Pharma, Agrochemicals & Nutraceuticals Therapeutic Category Our Product Category (GMP & Non-GMP) (Used in ~ 53 APIs) Pyridine, Picolines Amino Methyl Chloro/ Bromo/ Pyridines Fluoro Pyridines Antipyretic Analgesic Antifibrosis Off- Patented Amino Pyridines Hydroxy Methyl P
Slide 14: Financial Highlights: Q1 FY'23
Financial Highlights: Q1 FY’23
Slide 15: Chairmen's Message on Q1'FY23 Financial Results
Chairmen’s Message on Q1’FY23 Financial Results Mr. Shyam S Bhartia Mr. Hari S Bhartia Chairman Co-Chairman “We are glad to announce steady operational and financial performance in Q1’FY23, in the backdrop of inflationary headwinds leading to higher raw material and energy costs during the quarter.
Slide 16: Financial Highlights: Key Financial Parameters
Financial Highlights1 : Key Financial Parameters Highlights ₹ 1,166 Cr. ₹ 151 Cr. 12.9% ₹ 79 Cr. 6.8% ₹ 5.0 Q1’FY23 Sales EBITDA EBITDA (%) PAT PAT (%) EPS 2% YoY (47)% YoY (1,217) bps (53)% YoY (789) bps (53)% YoY Highlights ₹ 1,145 Cr. ₹ 287 Cr. 25.1% ₹ 168 Cr. 14.7% ₹ 10.6 Q1’FY22 Sales EBITDA EB
Slide 17: Q1 FY'23 Financial Results Summary
Jubilant Ingrevia – Q1 FY’23 Financial Results Summary Particulars1 Q1'FY22 Q1'FY23 YoY (%) FINANCIAL HIGHLIGHTS Revenue Speciality Chemicals 305 382 26% • Overall Revenue grew by 2% on YoY basis, mainly due to higher sales Nutrition & Health Solutions 167 150 (10%) performance by Speciality Chemica
Slide 18: Debt Profile – As on 30th June, 2022
Debt Profile – As on 30th June, 2022 Particulars1 30-Jun-21 31-Mar-22 30-Jun-22 Long Term Borrowings 227 100 - Short Term Borrowings 230 129 285 Total Gross Debt 457 229 285 Cash & Equivalent 70 49 57 Total Net Debt 386 181 228 YoY change -58% -41% We have successfully reduced our high cost long t
Slide 19: Balance Sheet – Key Parameters/Ratios
Balance Sheet – Key Parameters/Ratios (Pro-Forma2) Return On Capital Employed (RoCE) ## Return on Equity ## 27.8% 21.9% (%age) 20.2% 20.8% (%age) 16.4% 15.7% FY'21 FY'22 Q1'FY23 FY'21 FY22 Q1'FY23 Asset / Turnover and Return On Asset (RoA) Net Working Capital 15.0% 16.2% # 17.9% 55 Days 59 Day # 65
Slide 20: Business Segments Overview
BUSINESS SEGMENTS OVERVIEW
Slide 21: Speciality Chemicals – Segment Snapshot
Speciality Chemicals – Segment Snapshot Geographical Revenue Split (FY’22) 70+ Products (Pyridines & Picolines, Globally among Top 2 in Globally lowest cost Domestic Sales for International Cyanopyridines, (Pyridine+Beta); producer of Pyridine Piperidines, Consumption Globally #1 in 17 Pyridine offe
Slide 22: Speciality Chemicals Segment Highlights – Q1 FY'23
Speciality Chemicals Segment Highlights – Q1 FY’23 FINANCIAL HIGHLIGHTS Particulars1 Q1'FY22 Q1'FY23 YoY (%) Revenue 305 382 26% Specialty Chemicals revenue grew by 26% on YoY basis driven by Reported EBITDA 84 64 (24%) higher volume across product segments Reported EBITDA Margin (%) 27.7% 16.8%
Slide 23: Nutrition & Health Solutions – Segment Snapshot
Nutrition & Health Solutions – Segment Snapshot Global top 2 in Vitamin B3 Revenue Segmentation (FY’22) 5 Nutrition Ingredients & Domestic leader in Vitamin 100% in-house sourcing Domestic Sales for By End use B4 (Feed); Entered into of Beta Picoline (Key RM) for By Region Domestic Consumption Cosme
Slide 24: Nutrition & Health Solutions Segment Highlights – Q1 FY'23
Nutrition & Health Solutions Segment Highlights – Q1 FY’23 FINANCIAL HIGHLIGHTS Particulars1 Q1'FY22 Q1'FY23 YoY (%) Revenue 167 150 (10%) Nutritional Business sales was impacted mainly due to spread of Bird Reported EBITDA 27 19 (29%) Flu and Swine Flu in Europe US region, coupled with lower Repo
Slide 25: Chemical Intermediates – Segment Snapshot
Chemical Intermediates – Segment Snapshot Entered Value added Region wise Revenue Segmentation Acetic Anhydride: 9 Products Globally No. 2 in derivative Propionic For Segment (FY’22) (Acetic Anhydride, Ethyl Domestic Sales for Merchant Mkt Anhydride to RoW 3% Acetate ,Propionic Anhydride, Internatio
Slide 26: Chemical Intermediates Segment Highlights – Q1 FY'23
Chemical Intermediates Segment Highlights – Q1 FY’23 Particulars1 Q1'FY22 Q1'FY23 YoY (%) FINANCIAL HIGHLIGHTS Revenue 673 633 (6%) Chemical Intermediates business continue to witness strong Reported EBITDA 184 76 (58%) demand resulting into robust volume growth. Reported EBITDA Margin (%) 27.3% 1
Slide 27: Outlook & Growth Plans
Outlook & Growth Plans
Slide 28: Outlook
Outlook We expect overall healthy revenue growth during FY’23, led by volume growth in Specialty Chemicals & Chemical intermediate business segment. Commissioning of our three new capex of CDMO GMP, CDMO non-GMP and Acetic Anhydride is likely to aid the revenue growth. In the Nutrition & Health
Slide 29: Growth Capex Investment Plan – Business Wise
Growth Capex Investment Plan – Business Wise (Already Committed & to be Committed) Additional Capex to be Committed during FY’23 & FY’24~ Rs. 1150 Crores Committed till date ~ Rs. 900 Crores Estimated Cash Outflow (From FY’22 to Q1’FY23, Total Cash Outflow ~ Rs.312 Cr.) ~ (Rs.473 Cr, Rs.650 Cr. & Rs
Slide 30: Capacity Build-Up Plan – FY'22 to FY'25
Capacity Build- Up Plan – FY’22 to FY’25 (over Base of FY’22) Overall Capacity Build-Up Speciality Chemicals Capacity Build-Up Capacity Expansion Plan Capacity Expansion Plan (Overall capacity increase : 40.5% & CAGR: 12.0%) (Overall capacity increase: 44.7% & CAGR: 13.1%) 30.0% 32.3% 15.6% 1.5% 7.9
Slide 31: Structural Shift towards Speciality via Growth Capex Plans
Structural Shift towards Speciality via Growth Capex Plans Speciality & Nutrition will be 65% of Revenue up from present 46% post commissioning of our announced growth capex plans Revenue in INR Crores at Base price of FY’21 Speciality, Nutrition & Others: 65% Acetyls: 35% Speciality, Nutrition & Ot
Slide 32: Quality Business Excellence Sustainability
BUSINESS QUALITY SUSTAINABILITY EXCELLENCE
Slide 33: Jubilant Ingrevia: Global Accreditation
Jubilant Ingrevia: Global Accreditation Select Certifications Gajraula Bharuch Nira Samlaya Ambernath Responsible Care RC 14001:2015 ISO 9001:2015 ISO 22000:2005 ISO 14001:2015 ISO 45001:2018 FSSAI FAMI-QS HALAL KOSHER GMP State State FDA G
Slide 34: Business Excellence and Digital Transformation
Business Excellence and Digital Transformation Belt Competencies (FY’22) Digital Transformation Black Belts: 07 Green Belts: 103 Yellow Belts: 95 Our journey started in 2018 with an objective to improve Business Excellence Operational efficiency Tools & Processes Business & Supply chain proces
Slide 35: Bring Progressive Social Change via Strategic Multi-Stakeholder Partnership
Bring Progressive Social Change via Strategic Multi-Stakeholder Partnership Mission: To develop multi-stakeholder sustainable Aspiring to touch 1 Million Established models to bring about ‘social change’ involving the Lives through in 2007 knowledge generation & sharing, experiential lives social in
Slide 36: Sustainability Journey
Sustainability Journey 2001 2002 2003 2005 2008 2009 2010 2013 2015 2019 2021 Climate Became GRI Change Became UNGC SoFI Sustainability Sustainability Sustainability Jubilant Bhartia 1st EvoVadis Dow Jones ISO ISO 14000 14000 Sustainability Organization Mitigation Signatory and Sustainability Goals
Slide 37: Our Vision, Values, Promise and Philosophy
Our Vision, Values, Promise and Philosophy OUR PHILOSOPHY Caring Sharing Growing
Slide 38: For More Information
For More Information For Investors: Siddharth Rangnekar CDR India Pavleen Taneja Ph: +91 22 6645 1209 Ph: +91 120 436 1021 E-mail: siddharth@cdr-india.com E-mail: pavleen.taneja@jubl.com For Media: Clayton Dsouza Sudhakar Safaya Madison Public Relations Ph: +91 120 436 1034 E-mail: clayton.dsouza@ma
Slide 39: Appendix I: Income Statement – Q1'FY23
Appendix I: Income Statement – Q1’FY23 Particulars1 Q1'FY22 Q1'FY23 YoY (%) Total Revenue from Operations 1,145 1,166 2% Speciality Chemicals 305 382 26% Nutrition & Health Solutions 167 150 (10%) Chemical Intermediates 673 633 (6%) Total Expenditure 863 1,025 19% Other Income 6 10 69% Segment EBITD
Jubilant Ingrevia — Emkay Confluence - Ideas for a $5trn Economy 2022 on 6ix